After Hours
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. Earlier, Yahoo Finance discussed this stock as it revealed Arbutus Announces 2024 Corporate Objectives and Provides Financial Update.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
As a NASDAQ listed company, ABUS falls under the Healthcare sector while operating within the Biotechnology industry segment. At the end of the last regular session, the stock closed at $2.37 and fluctuated between $2.4000 as its day high and $2.3300 as its day low. The current market capitalization of Arbutus Biopharma Corp is $397.43M. A total of 1.01 million shares were traded on the day, compared to an average of 680.15K shares.
Aside from predicting where a stock will go, investors also consider insider trades as an indicator of the stock’s future direction. During the recent three months, ABUS has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 10 BUYs and 0 SELLs from insiders. Insiders purchased 1,062,200 shares during that period but sold 0.
In spite of price targets being rarely accurate, it tends to exert some kind influence from time to time, and was often accepted by the market as having some value. According to analysts who have offered 12-month price targets for ABUS in the last 3 months, the mean price target is $4.60 with high estimates of $6.00 and low estimates of $4.00. In terms of 52-week highs and lows, ABUS has a high of $3.14 and a low of $1.69.
As of this writing, ABUS has an earnings estimate of -$0.12 per share for the current quarter. EPS was calculated based on a consensus of 5 estimates, with a high estimate of -$0.1 per share and a lower estimate of -$0.13. The company reported an EPS of -$0.1 in the last quarter, which was 9.10% higher than expectations of -$0.11.
Balance Sheet Annually/Quarterly
The balance sheet of a company shows what assets and liabilities a company has, as well as the amount, equity investors have invested. With the help of this information, a company’s financial ratios can be calculated to give investors an overview of the company’s prospects. ABUS’s latest balance sheet shows that the firm has $155.32M in Cash & Short Term Investments as of fiscal 2021. There were $2.61M in debt and $11.22M in liabilities at the time. Its Book Value Per Share was $0.71, while its Total Shareholder’s Equity was $169.44M.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ABUS is Buy with a score of 5.00.
